Wang et al., investigated the role of CIP2A in mediating the synergism between temsirolimus (mTOR inhibitor) and cetuximab (EGFR inhibitor) in colon cancer and showed that temsirolimus mediated enhancement of the efficacy of cetuximab in colon cancer is CIP2A-dependent [114]. The gene discussed is EGFR; the disease is colonic neoplasm.